D3Pharmachemistry (Tiziano Bandiera), D3Compunet (Andrea Cavalli), D3Validation (Angelo Reggiani), Molecular Modeling and Drug Discovery (Marco DeVivo): DMPK characterization of new chemical entities
Proteomics studies for RNA biology (Irene Bozzoni, Gian Gaetano Tartaglia, Stefano Gustincich)
Neurobiology of miRNAs (Davide De Pietri Tonelli): study of alterations in protein expression following cell treatment with selected miRNAs
Genetics of Cognition (Francesco Papaleo): brain proteomics of Lgdel mouse model of autism
Genetics and epigenetics of behavior (Valter Tucci): role of brain neurotransmitters in Praeder-Willis syndrome
CNCS (Alessandro Gozzi): PK studies on clozapine and other DREADD compounds
Nanotechnology for precision medicine (Paolo Decuzzi): mechanism of action of nanoparticles mediated drug delivery
Polymers and biomaterials (Nicole Tirelli): lipid composition of extracellular vesicles
Istituto Giannina Gaslini (Dr. Pedemonte): CFTR Proteomics to investigate the basic pathological mechanisms of cystic fibrosis
Università di Genova, DINOGMI (Dr.Nobbio): lipidomics investigation to understand demyelination and remyelination processes
Istituto Ortopedico Rizzoli (Dr. Avnet): lipidomics of bone tumour spheroids to uncover metastatic processes
Neuromed – Istituto Oncologico Mediterraneo (Dr. Maglione): lipidomic characterization of a Huntington’s disease mouse model
niversità di Genova (Prof. Ameri): doxorubicin quantification in cardiac fibroblasts.
Università di Milano (Prof. Aureli): expression proteomics on a model of neurodegeneration
H2020 GRAPHENE FLAGSHIP – CORE 3 (2020-2023)
We are currently working on the properties of the biomolecular corona of graphene related materials and its role in the interaction with neuronal tissues.
FONDAZIONE FIBROSI CISTICA
We have an ongoing research project on the investigation of the metabolome and proteome primary bronchial epithelial cells to uncover new potential target for cystic fibrosis.
BIOMARKER DISCOVERY FOR ALZHEIMER'S DISEASE
We recently patented a set of circulating biomarkers for AD and we are currently undertaking validation activities.